Skip to content

Adult Intracranial Ependymoma

Adult Intracranial Ependydomas : Prognostic and Diagnostic Factors Assessment and Molecular Characterization

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00920335
Enrollment
192
Registered
2009-06-15
Start date
2009-03-31
Completion date
2013-07-31
Last updated
2014-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Ependymoma

Keywords

Adult intracranial ependymoma

Brief summary

Adult intracranial ependymoma is a relatively rare brain tumour entity, accounting for 2-5% of all intracranial neoplasms. The pertinent prognostic factors as well as the pattern of recurrence remain to be elucidated. According to several recent reports, the prognostic value of Karnofski performance status, tumour location, the extent of surgical removal, histological grade and even postoperative radiotherapy remain controversial. As a consequence, optimal therapeutic management of adult intracranial ependymomas remains an ongoing debate. For this reason, a retrospective study conducted by the French society of neurosurgery (SFNC), neuropathology (SFNP) and the association of the neuro-oncologists of French expression (ANOCEF) was undertaken and allowed to collect 258 cases coming from 25 centers, initially diagnosed as intracranial ependymomas between 1990 and 2004. Clinical and follow-up data of these patients are known and the paraffin embedded samples as well as the frozen tissues available have been centralized. Central pathological review of these 258 cases was conducted by two senior neuropathologists and confirmed the diagnosis of ependymoma in 152 cases, thus constituting the most important series of the literature. Few molecular studies were carried out on ependymomas. The investigators have the opportunity, based on this important series, to determine the clinicopathological criteria and the molecular markers who will allow a better characterization of the diagnosis and the prognosis of these tumors.

Interventions

OTHERtumoral sample

Ependymoma tumoral sample

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis later(posterior) than January, 1990 * Diagnosis previous to June, 2004 * Available postoperative MRI at the not dead patients during operating * Diagnosis of EICA held(retained) after centralized second reading * Absence of histories of radiotherapy and\\or chemotherapy for a brain damage

Exclusion criteria

* Diagnosis previous to January, 1990 * Diagnosis later(posterior) than June, 2004 · * Diagnosis of EICA not held(retained) after centralized second reading * Histories of radiotherapy and\\or chemotherapy for a brain damage

Design outcomes

Primary

MeasureTime frame
The primary objective is to identify a gene expression pattern associated with recurrence in adult intracranial ependymomas.3 years

Secondary

MeasureTime frame
Firstly to identify reliable molecular markers of the diagnosis of adult intracranial ependymomas and, secondly, to seek a molecular signature selectively expressed in sub-groups of ependymomas according to topography, age and histological grading.3 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026